Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.06
CPHD's Cash to Debt is ranked higher than
64% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. CPHD: 1.06 )
CPHD' s 10-Year Cash to Debt Range
Min: 0.88   Max: 11006.5
Current: 1.06

0.88
11006.5
Equity to Asset 0.45
CPHD's Equity to Asset is ranked higher than
61% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. CPHD: 0.45 )
CPHD' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.9
Current: 0.45

0.32
0.9
F-Score: 4
Z-Score: 6.19
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -7.25
CPHD's Operating margin (%) is ranked higher than
68% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.47 vs. CPHD: -7.25 )
CPHD' s 10-Year Operating margin (%) Range
Min: -233.91   Max: 1.37
Current: -7.25

-233.91
1.37
Net-margin (%) -10.67
CPHD's Net-margin (%) is ranked higher than
66% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.19 vs. CPHD: -10.67 )
CPHD' s 10-Year Net-margin (%) Range
Min: -220.28   Max: 0.95
Current: -10.67

-220.28
0.95
ROE (%) -14.68
CPHD's ROE (%) is ranked higher than
65% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. CPHD: -14.68 )
CPHD' s 10-Year ROE (%) Range
Min: -85.87   Max: 1.44
Current: -14.68

-85.87
1.44
ROA (%) -7.27
CPHD's ROA (%) is ranked higher than
67% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.78 vs. CPHD: -7.27 )
CPHD' s 10-Year ROA (%) Range
Min: -61.04   Max: 1.04
Current: -7.27

-61.04
1.04
ROC (Joel Greenblatt) (%) -17.74
CPHD's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. CPHD: -17.74 )
CPHD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -619.62   Max: 6.69
Current: -17.74

-619.62
6.69
Revenue Growth (3Y)(%) 17.30
CPHD's Revenue Growth (3Y)(%) is ranked higher than
94% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. CPHD: 17.30 )
CPHD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -15.4   Max: 56.7
Current: 17.3

-15.4
56.7
» CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CPHD Guru Trades in Q1 2014

PRIMECAP Management 2,270,400 sh (+4.19%)
Ron Baron 889,830 sh (+0.83%)
Columbia Wanger 8,360,000 sh (unchged)
Mario Gabelli 235,500 sh (-1.26%)
Columbia Wanger 7,467,000 sh (-10.68%)
» More
Q2 2014

CPHD Guru Trades in Q2 2014

Ron Baron 902,506 sh (+1.42%)
Columbia Wanger 7,467,000 sh (unchged)
Mario Gabelli 235,000 sh (-0.21%)
PRIMECAP Management 2,255,200 sh (-0.67%)
» More
Q3 2014

CPHD Guru Trades in Q3 2014

Columbia Wanger 7,745,200 sh (+3.73%)
Ron Baron 913,196 sh (+1.18%)
PRIMECAP Management 2,255,200 sh (unchged)
Mario Gabelli 234,500 sh (-0.21%)
» More
Q4 2014

CPHD Guru Trades in Q4 2014

PRIMECAP Management 2,310,100 sh (+2.43%)
Mario Gabelli 233,500 sh (-0.43%)
Ron Baron 884,701 sh (-3.12%)
Columbia Wanger 7,203,300 sh (-7.00%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 138.89
CPHD's Forward P/E is ranked higher than
76% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: 138.89 )
N/A
P/B 10.60
CPHD's P/B is ranked higher than
50% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.91 vs. CPHD: 10.60 )
CPHD' s 10-Year P/B Range
Min: 2.25   Max: 14.01
Current: 10.6

2.25
14.01
P/S 8.00
CPHD's P/S is ranked higher than
51% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.73 vs. CPHD: 8.00 )
CPHD' s 10-Year P/S Range
Min: 1.76   Max: 16.06
Current: 8

1.76
16.06
POCF 449.15
CPHD's POCF is ranked higher than
74% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 459.14 vs. CPHD: 449.15 )
CPHD' s 10-Year POCF Range
Min: 45.31   Max: 1642.33
Current: 449.15

45.31
1642.33
EV-to-EBIT -121.64
CPHD's EV-to-EBIT is ranked higher than
54% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: -121.64 )
CPHD' s 10-Year EV-to-EBIT Range
Min: -21113.7   Max: 744.4
Current: -121.64

-21113.7
744.4
Current Ratio 3.77
CPHD's Current Ratio is ranked higher than
79% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. CPHD: 3.77 )
CPHD' s 10-Year Current Ratio Range
Min: 1.36   Max: 14.11
Current: 3.77

1.36
14.11
Quick Ratio 2.80
CPHD's Quick Ratio is ranked higher than
77% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. CPHD: 2.80 )
CPHD' s 10-Year Quick Ratio Range
Min: 0.97   Max: 13.54
Current: 2.8

0.97
13.54
Days Inventory 193.43
CPHD's Days Inventory is ranked higher than
63% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. CPHD: 193.43 )
CPHD' s 10-Year Days Inventory Range
Min: 57.37   Max: 629.87
Current: 193.43

57.37
629.87
Days Sales Outstanding 53.42
CPHD's Days Sales Outstanding is ranked higher than
83% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.40 vs. CPHD: 53.42 )
CPHD' s 10-Year Days Sales Outstanding Range
Min: 40.78   Max: 124.41
Current: 53.42

40.78
124.41

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.20
CPHD's Price/Tangible Book is ranked higher than
56% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.00 vs. CPHD: 13.20 )
CPHD' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 20.68
Current: 13.2

2.1
20.68
Price/DCF (Projected) 34.30
CPHD's Price/DCF (Projected) is ranked higher than
74% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: 34.30 )
CPHD' s 10-Year Price/DCF (Projected) Range
Min: 24.01   Max: 58.32
Current: 34.3

24.01
58.32
Price/Median PS Value 1.20
CPHD's Price/Median PS Value is ranked higher than
72% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. CPHD: 1.20 )
CPHD' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 3.15
Current: 1.2

0.51
3.15
Earnings Yield (Greenblatt) -0.80
CPHD's Earnings Yield (Greenblatt) is ranked higher than
60% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CPHD: -0.80 )
CPHD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.8   Max: 0.4
Current: -0.8

-0.8
0.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:XEP.Germany,
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
» More Articles for CPHD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 29 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 10 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 
CEPHEID Reports Operating Results (10-Q) Aug 04 2010 
CEPHEID Reports Operating Results (10-Q) May 04 2010 

More From Other Websites
Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test Mar 24 2015
Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test Mar 24 2015
Stocks to Cure What Ails on World TB Day - Analyst Blog Mar 24 2015
On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF... Mar 24 2015
On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF... Mar 24 2015
CEPHEID Financials Mar 05 2015
10-K for Cepheid Feb 28 2015
CEPHEID Files SEC form 10-K, Annual Report Feb 26 2015
Cepheid to Webcast Upcoming Financial Presentations Feb 18 2015
Cepheid to Webcast Upcoming Financial Presentations Feb 18 2015
Cepheid's TB Test Wins FDA Clearance for Expanded Use - Analyst Blog Feb 16 2015
Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test Feb 13 2015
Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test Feb 13 2015
Cepheid Strong on Q4, Global Expansion; Currency Woes Stay - Analyst Blog Feb 12 2015
Cepheid Inc (CPHD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Feb 11 2015
Cepheid Posts Breakeven Earnings; System Placements High - Analyst Blog Jan 30 2015
Cepheid reports 4Q loss Jan 29 2015
Cepheid reports 4Q loss Jan 29 2015
Cepheid Earnings Call scheduled for 5:00 pm ET today Jan 29 2015
Cepheid Reports Fourth Quarter And Full Year 2014 Results Jan 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK